-
公开(公告)号：US5481007A
公开(公告)日：1996-01-02
申请号：US201926
申请日：1994-02-23
申请人： K. C. Nicolaou , Christopher F. Claiborne , Philippe G. Nantermet , Elias A. Couladouros , Erik J. Sorensen
发明人： K. C. Nicolaou , Christopher F. Claiborne , Philippe G. Nantermet , Elias A. Couladouros , Erik J. Sorensen
IPC分类号： C07C43/178 , C07C69/00 , C07C69/013 , C07C69/757 , C07D305/14 , C07D317/72 , C07D319/08 , C07D493/08 , C07F7/18 , C07D317/70
CPC分类号： C07D317/72 , C07C43/1788 , C07C69/00 , C07C69/013 , C07C69/757 , C07D305/14 , C07D319/08 , C07D493/08 , C07F7/1852 , C07C2101/16 , C07C2103/00
摘要： Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.
摘要翻译： 通过收敛合成可获得的生物活性ABC紫杉醇具有完整的AB环框架的紫杉醇，包括C13侧链和芳香C环，其代替在天然紫杉醇上发现的CD环系统。 芳族C环可以是取代或未取代的。 还披露了ABC紫杉烷的MPT衍生物。
-
公开(公告)号：US09988384B2
公开(公告)日：2018-06-05
申请号：US13217729
申请日：2011-08-25
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
-
公开(公告)号：US20110312943A1
公开(公告)日：2011-12-22
申请号：US13217729
申请日：2011-08-25
CPC分类号： C07D487/04
摘要： The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
-
公开(公告)号：US07217716B2
公开(公告)日：2007-05-15
申请号：US10470561
申请日：2002-02-20
申请人： Christopher F. Claiborne , David A. Claremon , Brian E. Libby , John W. Butcher , John A. McCauley , Nigel J. Liverton , Peter M. Munson , Kevin T. Nguyen , Brian Phillips , Wayne Thompson
发明人： Christopher F. Claiborne , David A. Claremon , Brian E. Libby , John W. Butcher , John A. McCauley , Nigel J. Liverton , Peter M. Munson , Kevin T. Nguyen , Brian Phillips , Wayne Thompson
IPC分类号： C07D401/12 , A61K31/444
CPC分类号： C07D409/14 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D451/02 , C07D471/04 , C07D473/16 , C07D473/34 , C07D475/08
摘要： Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain
摘要翻译： 由式（I）表示的化合物：（I）或其药学上可接受的盐作为可用于缓解疼痛的NMDA NR2B拮抗剂是有效的
-
公开(公告)号：US06376530B1
公开(公告)日：2002-04-23
申请号：US09550972
申请日：2000-04-17
IPC分类号： C07D20944
CPC分类号： C07D209/48 , A61K31/4035 , A61K31/472 , C07D217/22
摘要： The invention encompasses novel compounds of Formula I as well as a method of treating NMDA mediated diseases comprising administration to a patient in need of such treatment a non-toxic amount of a compound of Formula I effective to block the NMDA NR2B receptor sub-unit. The invention also encompasses certain pharmaceutical compositions for the treatment of NMDA mediated diseases comprising compounds of Formula I and a pharmaceutically acceptable carrier.
摘要翻译： 本发明包括式I的新化合物以及治疗NMDA介导的疾病的方法，包括向需要这种治疗的患者施用无毒量的有效阻断NMDA NR2B受体亚单位的式I化合物。 本发明还包括用于治疗包含式I化合物和药学上可接受的载体的NMDA介导的疾病的某些药物组合物。
-
公开(公告)号：US06303637B1
公开(公告)日：2001-10-16
申请号：US09422500
申请日：1999-10-21
申请人： Jianming Bao , Andrew Kotliar , Frank Kayser , William H. Parsons , Kathleen M. Rupprecht , Christopher F. Claiborne , David A. Claremon , Nigel Liverton , Wayne J. Thompson
发明人： Jianming Bao , Andrew Kotliar , Frank Kayser , William H. Parsons , Kathleen M. Rupprecht , Christopher F. Claiborne , David A. Claremon , Nigel Liverton , Wayne J. Thompson
IPC分类号： A61K31445
CPC分类号： C07D211/96 , A61K31/445 , A61K31/47 , A61K31/52 , A61K31/535 , A61K31/70 , A61K38/13 , A61K45/06 , C07D211/26 , A61K31/365 , A61K31/16 , A61K2300/00
摘要： The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
摘要翻译： 本发明涉及可用作治疗自身免疫性疾病，心律失常等的钾通道抑制剂的一类式I的杂环化合物。
-
公开(公告)号：US06194458B1
公开(公告)日：2001-02-27
申请号：US09422499
申请日：1999-10-21
申请人： Robert K. Baker , Jianming Bao , Frank Kayser , Andrew Kotliar , William H. Parsons , Kathleen M. Rupprecht , Christopher F. Claiborne , David A. Claremon , Nigel Liverton , Wayne J. Thompson
发明人： Robert K. Baker , Jianming Bao , Frank Kayser , Andrew Kotliar , William H. Parsons , Kathleen M. Rupprecht , Christopher F. Claiborne , David A. Claremon , Nigel Liverton , Wayne J. Thompson
IPC分类号： A61K3122
CPC分类号： C07D307/79 , A61K45/06 , C07C235/60 , C07C271/20
摘要： This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
摘要翻译： 本发明涉及一般结构式I的苯甲酰胺钾通道抑制剂。本发明的化合物可用于治疗自身免疫性疾病，预防外来器官移植排斥和相关疾病，疾病和疾病以及心律失常。 也包括本发明范围的药物制剂，其包含式I化合物和药物载体，以及包含式I化合物，一种或多种免疫抑制化合物和药物载体的药物制剂。
-
公开(公告)号：US5760240A
公开(公告)日：1998-06-02
申请号：US527377
申请日：1995-09-13
申请人： K. C. Nicolaou , Christopher F. Claiborne , Philippe G. Nantermet , Elias A. Couladouros , Erik J. Sorenson
发明人： K. C. Nicolaou , Christopher F. Claiborne , Philippe G. Nantermet , Elias A. Couladouros , Erik J. Sorenson
IPC分类号： C07C43/178 , C07C69/00 , C07C69/013 , C07C69/757 , C07D305/14 , C07D317/72 , C07D319/08 , C07D493/08 , C07F7/18 , C07D213/89
CPC分类号： C07D317/72 , C07C43/1788 , C07C69/00 , C07C69/013 , C07C69/757 , C07D305/14 , C07D319/08 , C07D493/08 , C07F7/1852 , C07C2101/16 , C07C2103/00
摘要： Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.
-
公开(公告)号：US08026246B2
公开(公告)日：2011-09-27
申请号：US11985277
申请日：2007-11-14
IPC分类号： A61K31/505 , C07D491/00
CPC分类号： C07D487/04
摘要： The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 特别地，本发明提供了极光A激酶的有效抑制剂，包含该化合物的药物组合物，以及使用该化合物治疗癌症的方法。
-
30.发明授权Pyridobenzazepine compounds and methods for inhibiting mitotic progression 有权吡啶并苯并吖嗪化合物和抑制有丝分裂进展的方法公开(公告)号：US07718648B2
公开(公告)日：2010-05-18
申请号：US11890406
申请日：2007-08-06
IPC分类号： A61P35/00 , A61K31/55 , C07D487/00
CPC分类号： C07D471/04
摘要： This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 特别地，本发明提供抑制极光激酶的化合物，包含该化合物的药物组合物，以及使用该化合物治疗癌症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.053 秒)
